Show an ad over header. AMP

Trump's big health promises ignore the coronavirus pandemic's reality

President Trump's convention speech last night did not frame the coronavirus as a thing that's over, the way some of the other programming during the convention had.

What happened: He acknowledged the 180,000 Americans who have died, and the toll on their families, and used the present and future tenses to describe a response that is still ongoing, but he painted a rosier picture of the U.S. response, and made bolder predictions, than the facts fully support.


Trump promised that the U.S. "will produce a vaccine by the end of the year, or maybe even sooner."

  • There's just no way to promise that — at least not responsibly. The progress so far has been encouraging, but all of the leading candidates are still being tested to find out whether they work.

He also said convalescent plasma — the treatment the FDA controversially authorized last week — will "save thousands of lives."

  • The evidence is much thinner than that; clinical studies into its effectiveness are still ongoing.

As for the rest of his health care agenda, Trump made fairly typical exaggerations of his record on drug prices. It is certainly true that the administration has proposed some ambitious plans to rein in pharmaceutical pricing, but it has hardly enacted any of those proposals.

  • And he said that in a second term, he would "end surprise medical billing, require price transparency, and further reduce the cost of prescription drugs and health insurance premiums."
  • The administration has required price transparency for hospitals, despite the industry's staunch opposition, and it also imposed new price disclosure rules on drugs, though they have been blocked by the courts.

The bottom line: There wasn't much here that you haven't already heard, and the reality of the coronavirus remains what you know it to be: The U.S. has handled this far worse than any other rich country on Earth.

Trump pushes to expand ban against anti-racism training to federal contractors

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Keep reading... Show less

GoodRx prices IPO at $33 per share, valued at $12.7 billion

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Keep reading... Show less

Scoop: Meadows puts agencies on notice about staff shake-up

White House chief of staff Mark Meadows told administration officials Monday to expect senior aides to be replaced at many government agencies, according to an internal email obtained by Axios.

Behind the scenes: Meadows asked the director of the White House Presidential Personnel Office John McEntee "to look at replacing the White House Liaisons (WHLs) at many of your agencies," according to the email. "John will be working with outgoing liaisons to explore other opportunities."

Keep reading... Show less

White House ricin package suspect allegedly urged Trump to "give up for this election"

A Canadian woman allegedly mailed a letter addressed to President Trump containing the poison ricin and the threat "give up and remove your application for this election," court papers filed Tuesday show.

Driving the news: Pascale Cecile Veronique Ferrier, 53, was arrested trying to enter New York from Canada on Sunday. She appeared briefly in a Buffalo, N.Y., courtroom where a judge entered a not guilty plea on her behalf to the charge of threatening the president, per CBC.

Keep reading... Show less

House Democrats, Trump administration strike deal to avert government shutdown

House Democrats have reached a deal with the Trump administration on legislation to fund the government through Dec. 11, Speaker Nancy Pelosi (D-Calif.) announced Tuesday.

Why it matters: The deal will avert a government shutdown when funding expires in eight days. Pelosi and House Majority Leader Steny Hoyer (D-Md.) said earlier that they hoped to hold a vote on the legislation on Tuesday evening.

Keep reading... Show less

Remote work won't kill your office

We can officially declare the 9-to-5, five-days-a-week, in-office way of working dead. But offices themselves aren't dead. And neither are cities.

The big picture: Since the onset of pandemic-induced telework, companies have oscillated between can't-wait-to-go-back and work-from-home-forever. Now, it's becoming increasingly clear that the future of work will land somewhere in the middle — a remote/in-person hybrid.

Keep reading... Show less

FBI: Foreign actors likely to sow disinformation about delays in election results

The FBI and Cybersecurity and Infrastructure Security Agency released a public service announcement on Tuesday warning that mail-in ballots "could leave officials with incomplete results on election night," and that foreign actors are likely to spread disinformation about the delays.

The bottom line: The agencies called on the public to "critically evaluate the sources of the information they consume and to seek out reliable and verified information from trusted sources," including state and local election officials.

Keep reading... Show less

The big business of immigrant detention

Around 70% of all immigration detention centers are run by private companies, including the one at the heart of a new whistleblower complaint that alleges systemic medical neglect and malpractice.

Axios Re:Cap digs into the business of immigrant detention, including oversight and profit incentives, with Jonathan Blitzer, a staff writer for the New Yorker who’s covered the subject for years.

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories